A federal judge has thrown out patents protecting Allergan’s blockbuster dry-eye drug Restasis, and has criticised its related deal with a Native American tribe. In the ruling US Circuit Judge ...

But with Novartis failing to convince European regulators about the merits of Xiidra last year, and Allergan's ageing Restasis potentially facing generic competition, there’s a lot to play for ...

Harrow's products compete against established generics, and it heavily relies on marketing and sales force expansion to drive ...

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and ...

Bausch + Lomb is headed by Brent Saunders, a longtime pharmaceutical executive known for leading Allergan into a much ... antitrust issues given its Restasis has a 45% share of the prescription ...

On August 13, 2024, the Federal Circuit issued its decision in Allergan USA, Inc. v. MSN Laboratories Private Ltd., No. 24-1061,[1] which limits the scope of obviousness-type double patenting for ...

Pfizer will bring together its drugs such as Lipitor, Viagra and nerve pain treatment Lyrica with Allergan's Namenda memory loss treatment, Restasis dry eye medication and other leading eye-care ...

It was then that Actavis, a drug company that specializes in generic drugs and over-the-counter products, scooped up Allergan for a neat $66 billion. Here's a photo of Actavis CEO Brenton Saunders ...

Allergan Aesthetics intends to develop onabotulinumtoxinA treatment for MMP in additional global markets and expand the use of BOTOX ® Cosmetic in the lower face. IRVINE, Calif., Sept.

Opinions expressed by Forbes Contributors are their own. Celia Shatzman writes about fashion, beauty and grooming. “Allē has had a loyalty program since 2020 and there was a predecessor program ...

Bausch + Lomb is headed by Brent Saunders, a longtime pharmaceutical executive known for leading Allergan into a much ... antitrust issues given its Restasis has a 45% share of the prescription ...